Vericel (VCEL) Projected to Release Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.0575 per share and revenue of $77.95 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Vericel Stock Performance

NASDAQ:VCEL opened at $41.09 on Wednesday. The stock’s fifty day moving average price is $40.51 and its two-hundred day moving average price is $38.70. Vericel has a 52-week low of $28.95 and a 52-week high of $49.32. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 87.43 and a beta of 1.08.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Canaccord Genuity Group set a $60.00 target price on Vericel in a research note on Thursday, July 30th. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Truist Financial decreased their price target on Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Vericel in a report on Tuesday, July 28th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Vericel currently has a consensus rating of “Moderate Buy” and an average price target of $57.20.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.